BioShin

company

About

BioShin is a clinical stage biopharmaceutical company.

  • Shanghai,Shanghai,China
  • 1 - 10

Details

Last Funding Type
Series A
Last Funding Money Raised
$60M
Industries
Biotechnology,Health Care,Life Science,Pharmaceutical
Founded date
Jan 1, 2013
Number Of Employee
1 - 10
Operating Status
Active
Legal Name
BioShin Ltd.

BioShin is a wholly owned subsidiary of Biohaven Pharmaceuticals, a public biotech company. BioShin is a clinical stage biopharmaceutical company focused on developing medicines. It has proven leadership from global industry and academic settings and a portfolio of innovative, late stage product candidates targeting neurological and neuropsychiatric diseases, including rare disorders.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$60M
BioShin has raised a total of $60M in funding over 2 rounds. Their latest funding was raised on Sep 28, 2020 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 28, 2020 Series A $60M 5 OrbiMed Detail

Investors

Number of Lead Investors
Number of Investors
1
5
BioShin is funded by 5 investors. OrbiMed and Cormorant Asset Management are the most recent investors.
Investor Name Lead Investor Funding Round
OrbiMed Yes Series A
Cormorant Asset Management Series A
HBM Healthcare Investments AG Series A
Surveyor Capital Series A
Suvretta Capital Management Series A

Employee Profiles

Number of Employee Profiles
4
BioShin has 4 current employee profiles, including Board member David Wang
Board member
Board member
Executive
Board member